Escherichia coli (E coli) Infections Treatment & Management

1. Bennett JE, Dolin R, Blaser MJ. Enterobacteriaceae. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. 9th. Philadelphia, PA: Elsevier; 2020. 2673.

2. Bennett JE, Dolin R, Blaser MJ. Enterobacteriaceae. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. 9th. Philadelphia, PA: Elsevier; 2020. 2679.

3. Kermorvant-Duchemin, E; Laborie, S; Rabilloud, M; Lapillonne, A; Claris, O. Outcome and prognostic factors in neonates with septic shock. Pediatric Critical Care Medicine. March 2008. 9:186-191. [QxMD MEDLINE Link]. [Full Text].

4. Khadka, P, Khadka P, Thapaliya, J, Bikram Karkee, et al. Fatal strongyloidiasis after corticosteroid therapy for presumed chronic obstructive pulmonary disease. JMM Case Reports. Sep 2018. 5:[QxMD MEDLINE Link]. [Full Text].

5. Medina, M; Castillo-Pino, E. An introduction to the epidemiology and burden of urinary tract infections. Therapeutic Advances in Urology. 02May2019. [QxMD MEDLINE Link]. [Full Text].

6. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011 Nov 10. 365(19):1771-80. [QxMD MEDLINE Link].

7. Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med. 2011 Nov 10. 365(19):1763-70. [QxMD MEDLINE Link].

8. Camins BC, Marschall J, De Vader SR, Maker DE, Hoffman MW, Fraser VJ. The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia. J Hosp Med. 2011 Jul. 6(6):344-9. [QxMD MEDLINE Link]. [Full Text].

9. Walmsley RS, David DB, Allan RN, Kirkby GR. Bilateral endogenous Escherichia coli endophthalmitis: a devastating complication in an insulin-dependent diabetic. Postgrad Med J. 1996 Jun. 72(848):361-3. [QxMD MEDLINE Link].

10. [Guideline] Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine. October 2019. 200:e45-e67. [Full Text].

11. [Guideline] Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 21 March 2019. 68:e83-e110. [Full Text].

12. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010 Jan 15. 50 (2):133-64. [QxMD MEDLINE Link].

13. McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother. 2010 Sep. 54(9):3790-8. [QxMD MEDLINE Link].

14. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008 Mar. 8(3):159-66. [QxMD MEDLINE Link].

15. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect. 2007 Sep. 55(3):254-9. [QxMD MEDLINE Link].

16. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, et al. Community-associated extended-spectrum ß-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013 Mar. 56(5):641-8. [QxMD MEDLINE Link]. [Full Text].

17. Batard E, Ollivier F, Boutoille D, Hardouin JB, Montassier E, Caillon J, et al. Relationship between hospital antibiotic use and quinolone resistance in Escherichia coli. Int J Infect Dis. 2012 Nov 22. [QxMD MEDLINE Link].

18. Karlowsky JA, Denisuik AJ, Lagacé-Wiens PR, Adam HJ, Baxter MR, Hoban DJ, et al. In Vitro Activity of Fosfomycin against Escherichia coli Isolated from Patients with Urinary Tract Infections in Canada; CANWARD Surveillance Study. Antimicrob Agents Chemother. 2013 Dec 9. [QxMD MEDLINE Link].

19. Agustin ET, Gill V, Domenico P. CSF gram stain in meningitis. Intern Med. 1994. 15:14-24.

20. Barnett BJ, Stephens DS. Urinary tract infection: an overview. Am J Med Sci. 1997 Oct. 314(4):245-9. [QxMD MEDLINE Link].

21. Boam WD, Miser WF. Acute focal bacterial pyelonephritis. Am Fam Physician. 1995 Sep 1. 52(3):919-24. [QxMD MEDLINE Link].

22. Bohnen JM. Antibiotic therapy for abdominal infection. World J Surg. 1998 Feb. 22(2):152-7. [QxMD MEDLINE Link].

23. Bonoan JT, Mehra S, Cunha BA. Emphysematous pyelonephritis. Heart Lung. 1997 Nov-Dec. 26(6):501-3. [QxMD MEDLINE Link].

24. Carpenter HA. Bacterial and parasitic cholangitis. Mayo Clin Proc. 1998 May. 73(5):473-8. [QxMD MEDLINE Link].

25. Childs SJ. Current concepts in the treatment of urinary tract infections and prostatitis. Am J Med. 1991 Dec 30. 91(6A):120S-123S. [QxMD MEDLINE Link].

26. Cunha BA. Abdominal pain in patients with diabetis mellitus. Infect Dis Prac. 1997. 21:14-5.

27. Cunha BA. Acute acalculous cholecystitis. Infect Dis Prac. 1997. 21:70-1.

28. Cunha BA. Acute and chronic bacterial prostatitis. Infect Dis Prac. 1994. 18:78-9.

29. Cunha BA. Antibiotic concentration dependent susceptibility of urinary tract isolates. Antib Clinician. 1999. 3:57-8.

30. Cunha BA. Quinolones: Clinical aspects. Antib Clinician. 1998. 2:129-35.

31. Cunha BA. The fluoroquinolones for urinary tract infections: a review. Adv Ther. 1994 Nov-Dec. 11(6):277-96. [QxMD MEDLINE Link].

32. Cunha BA. Therapeutic approach in treating UTIs. Antib Clinician. 1998. 2(S2):35-40.

33. Cunha BA. Urine gram stain in urosepsis. Intern Med. 1997. 18:75-8.

34. Cunha BA. Urosepsis. J Crit Ill. 1997. 12:616-25.

35. Donnenberg MS, Kaper JB. Enteropathogenic Escherichia coli. Infect Immun. 1992 Oct. 60(10):3953-61. [QxMD MEDLINE Link].

36. DuPont HL. Travellers' diarrhoea: contemporary approaches to therapy and prevention. Drugs. 2006. 66(3):303-14. [QxMD MEDLINE Link].

37. Eisenstein BI, Jones GW. The spectrum of infections and pathogenic mechanisms of Escherichia coli. Adv Intern Med. 1988. 33:231-52. [QxMD MEDLINE Link].

38. Glandt M, Adachi JA, Mathewson JJ, Jiang ZD, DiCesare D, Ashley D. Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin. Clin Infect Dis. 1999 Aug. 29(2):335-8. [QxMD MEDLINE Link].

39. Gold R. Bacterial meningitis--1982. Am J Med. 1983 Jul 28. 75(1B):98-101. [QxMD MEDLINE Link].

40. Hansing CE, Allen VD, Cherry JD. Escherichia coli endocarditis. A review of the literature and a case study. Arch Intern Med. 1967 Oct. 120(4):472-7. [QxMD MEDLINE Link].

41. Harrington SM, Dudley EG, Nataro JP. Pathogenesis of enteroaggregative Escherichia coli infection. FEMS Microbiol Lett. 2006 Jan. 254(1):12-8. [QxMD MEDLINE Link].

42. Harvey D, Holt DE, Bedford H. Bacterial meningitis in the newborn: a prospective study of mortality and morbidity. Semin Perinatol. 1999 Jun. 23(3):218-25. [QxMD MEDLINE Link].

43. Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev. 1991 Jan. 4(1):80-128. [QxMD MEDLINE Link].

44. Jonas M, Cunha BA. Bacteremic Escherichia coli pneumonia. Arch Intern Med. 1982 Nov. 142(12):2157-9. [QxMD MEDLINE Link].

45. Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am. 1995 Jul. 79(4):705-19. [QxMD MEDLINE Link].

46. Koutkia P, Mylonakis E, Flanigan T. Enterohemorrhagic Escherichia coli O157:H7--an emerging pathogen. Am Fam Physician. 1997 Sep 1. 56(3):853-6, 859-61. [QxMD MEDLINE Link].

47. Lepelletier D, Caroff N, Reynaud A, Richet H. Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains. Clin Infect Dis. 1999 Sep. 29(3):548-52. [QxMD MEDLINE Link].

48. Lerner AM. The gram-negative bacillary pneumonias. Dis Mon. 1980 Nov. 27(2):1-56. [QxMD MEDLINE Link].

49. McDonald MI. Pyogenic liver abscess: diagnosis, bacteriology and treatment. Eur J Clin Microbiol. 1984 Dec. 3(6):506-9. [QxMD MEDLINE Link].

50. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet. 1998 Oct 10. 352(9135):1207-12. [QxMD MEDLINE Link].

51. Moon HW. Pathogenesis of enteric diseases caused by Escherichia coli. Adv Vet Sci Comp Med. 1974. 18(0):179-211. [QxMD MEDLINE Link].

52. Neu HC. Infections due to gram-negative bacteria: an overview. Rev Infect Dis. 1985 Nov-Dec. 7 Suppl 4:S778-82. [QxMD MEDLINE Link].

53. Nordmann P. Trends in beta-lactam resistance among Enterobacteriaceae. Clin Infect Dis. 1998 Aug. 27 Suppl 1:S100-6. [QxMD MEDLINE Link].

54. Ortega AM, Cunha BA. Acute prostatitis. Contemp Urol. 1997. 18:73-80.

55. Palmer DL. Microbiology of pneumonia in the patient at risk. Am J Med. 1984 May 15. 76(5A):53-60. [QxMD MEDLINE Link].

56. Phillips AD, Frankel G. Mechanisms of gut damage by Escherichia coli. Baillieres Clin Gastroenterol. 1997 Sep. 11(3):465-83. [QxMD MEDLINE Link].

57. Roberts JA. Pyelonephritis, cortical abscess, and perinephric abscess. Urol Clin North Am. 1986 Nov. 13(4):637-45. [QxMD MEDLINE Link].

58. Savatta D, Cunha BA. Acute pyelonephritis and its mimics: Xanthogranulomaotus pyelonephritis and malacoplakia. Infect Dis Prac. 1996. 20:86-8.

59. Schimpff SC. Gram-negative bacteremia. Support Care Cancer. 1993 Jan. 1(1):5-18. [QxMD MEDLINE Link].

60. Schindzielorz A, Edberg SC, Bia FJ. Strongyloides stercoralis hyperinfection and central nervous system involvement in a patient with relapsing polychondritis. South Med J. 1991 Aug. 84(8):1055-7. [QxMD MEDLINE Link].

61. Shea KW, Cunha BA. Escherichia coli sternal osteomyelitis after open heart surgery. Heart Lung. 1995 Mar-Apr. 24(2):177-8. [QxMD MEDLINE Link].

62. Tabacof J, Feher O, Katz A, et al. Strongyloides hyperinfection in two patients with lymphoma, purulent meningitis, and sepsis. Cancer. 1991 Oct 15. 68(8):1821-3. [QxMD MEDLINE Link].

63. Tan JS, File TM. Urinary tract infections in obstetrics and gynecology. J Reprod Med. 1990 Mar. 35(3 Suppl):339-42. [QxMD MEDLINE Link].

64. Tenner SM, Yadven MW, Kimmel PL. Acute pyelonephritis. Preventing complications through prompt diagnosis and proper therapy. Postgrad Med. 1992 Feb 1. 91(2):261-8. [QxMD MEDLINE Link].

65. Tice AD. Short-course therapy of acute cystitis: a brief review of therapeutic strategies. J Antimicrob Chemother. 1999 Mar. 43 Suppl A:85-93. [QxMD MEDLINE Link].

66. Wanke CA. Escherichia coli. J Diarrhoeal Dis Res. 1988 Mar. 6(1):1-5. [QxMD MEDLINE Link].

67. Weinberger M, Cytron S, Servadio C, et al. Prostatic abscess in the antibiotic era. Rev Infect Dis. 1988 Mar-Apr. 10(2):239-49. [QxMD MEDLINE Link].

68. Westphal JF, Brogard JM. Biliary tract infections: a guide to drug treatment. Drugs. 1999 Jan. 57(1):81-91. [QxMD MEDLINE Link].

69. Whipp SC, Rasmussen MA, Cray WC Jr. Animals as a source of Escherichia coli pathogenic for human beings. J Am Vet Med Assoc. 1994 Apr 15. 204(8):1168-75. [QxMD MEDLINE Link].

Ryan P Collier, MD, FACP Infectious Disease Physician, Chair, Infection Prevention and Control, Mike O'Callaghan Military Medical Center, Nellis AFB; Assistant Professor of Medicine, Uniformed Services University of the Health Sciences School of Medicine

Ryan P Collier, MD, FACP is a member of the following medical societies: American College of Physicians, American Medical Association, Infectious Diseases Society of America, Texas Infectious Disease Society, The Society of Federal Health Professionals (AMSUS)

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Charles V Sanders, MD Edgar Hull Professor and Chairman, Department of Internal Medicine, Professor of Microbiology, Immunology and Parasitology, Louisiana State University School of Medicine in New Orleans; Medical Director, Medicine Hospital Center, Charity Hospital and Medical Center of Louisiana at New Orleans; Consulting Staff, Ochsner Medical Center

Charles V Sanders, MD is a member of the following medical societies: Alliance for the Prudent Use of Antibiotics, Alpha Omega Alpha, American Association for Physician Leadership, American Association for the Advancement of Science, American Association of University Professors, American Clinical and Climatological Association, American College of Physicians, American Federation for Medical Research, American Geriatrics Society, American Lung Association, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Association for Professionals in Infection Control and Epidemiology, Association of American Medical Colleges, Association of American Physicians, Association of Professors of Medicine, Infectious Disease Society for Obstetrics and Gynecology, Infectious Diseases Society of America, Louisiana State Medical Society, Orleans Parish Medical Society, Royal Society of Medicine, Sigma Xi, The Scientific Research Honor Society, Society of General Internal Medicine, Southeastern Clinical Club, Southern Medical Association, Southern Society for Clinical Investigation, Southwestern Association of Clinical Microbiology, The Foundation for AIDS Research

Disclosure: Receives royalties from Baxter International for: Takeda-receives royalties; UpToDate-receives royalties.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Chi Hiong U Go, MD Assistant Professor, Department of Internal Medicine, Texas Tech University Health Science Center at Odessa

Chi Hiong U Go, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine

Disclosure: Nothing to disclose.

Larry I Lutwick, MD, FACP Editor-in-Chief, ID Cases; Moderator, Program for Monitoring Emerging Diseases; Adjunct Professor of Medicine, State University of New York Downstate College of Medicine

Larry I Lutwick, MD, FACP is a member of the following medical societies: American Association for the Advancement of Science, American Association for the Study of Liver Diseases, American College of Physicians, American Federation for Clinical Research, American Society for Microbiology, Infectious Diseases Society of America, Infectious Diseases Society of New York, International Society for Infectious Diseases, New York Academy of Sciences, Veterans Affairs Society of Practitioners in Infectious Diseases

Disclosure: Nothing to disclose.

Tarun Madappa, MD, MPH Attending Physician, Department of Pulmonary and Critical Care Medicine, Christus Spohn-Shoreline Hospital

Tarun Madappa, MD, MPH is a member of the following medical societies: American College of Chest Physicians, American Thoracic Society

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Eleftherios Mylonakis, MD, to the development and writing of this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article